logo-loader
viewMicro Focus International plc

Micro Focus raises revenue guidance for year just ended

Brian McArthur-Muscroft is to be to new CFO as Chris Kennedy is getting with the programme at ITV. The new bean-counter will join Micro-Focus as an employee this month and will assume his executive duties in the first quarter of 2019, at a date to be announced

Rising dollar
The group saw "an improved revenue trajectory" in the second half of the fiscal year just ended

Chris Kennedy, the chief financial officer (CFO) of Micro Focus International PLC (LON:MCRO), is to jump ship to join ITV.

Kennedy obviously gets around a bit because he was CFO of easyJet for five years until 2015, working under Carolyn McCall, who is now the boss of ITV.

READ: ITV boss Carolyn McCall poaches former easyJet colleague as CFO

Kennedy will leave Micro Focus in the first quarter of next year. He will be replaced by Brian McArthur-Muscroft, who has held a variety of senior management positions, including the role of CFO at TeleCity Group PLC and most recently as CFO of Paysafe Group PLC.

The legacy software group said trading had continued in line with the board’s expectations, with the trajectory of the top-line showing an improvement in the second half of the fiscal year (to October 31).

As a result, constant currency revenue will be around the better end of the guidance range, which was for a fall of 6-9% on last year’s revenue.

Trading has also been consistent with the group's adjusted underlying earnings margin guidance of roughly 37% at the midpoint of the revenue range.

Taking into account the US$171mln spent on share buybacks in the period, net debt is expected to be in line with guidance.

Talking of the share repurchase programme, Micro Focus said it intends to recommence this, with up to US$400mln of shares – including the US$171mln already spent – earmarked for buy-back.

Shares in Micro Focus were up 2.2% at 1,258p.

Quick facts: Micro Focus International plc

Price: 1102.8 GBX

LSE:MCRO
Market: LSE
Market Cap: £3.68 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Summit Therapeutics' Glyn Edwards talks US$50mln backing and ridinilazole...

Summit Therapeutics PLC's (LON:SUMM, NASDAQ:SMMT) CEO Glyn Edwards sat down with Proactive London's Andrew Scott following the news of a US$50mln funding deal with biotech billionaire Bob Duggan. The investment will help get the company’s next-generation antibiotic through phase III clinical...

8 hours, 32 minutes ago

RNS

Total Voting Rights

1 week, 1 day ago

Notification of major holdings

1 week, 5 days ago

Trading update

2 weeks, 6 days ago

Director Declaration

3 weeks, 1 day ago

Total Voting Rights

on 1/11/19

2 min read